Figure 6: Alterations in IFNγ pathway signalling impact on patient survival. | Nature Communications

Figure 6: Alterations in IFNγ pathway signalling impact on patient survival.

From: Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

Figure 6

(a) Truncating mutations, homozygous deletions and low protein levels of IFNGR1, IFNGR2, JAK1, JAK2, STAT1 and IRF1 define a subset of melanoma patients in the TCGA data set with decreased survival. Of 479 patients with data on aberrations, 468 had available survival data. Log-rank P value shown. (b) Kaplan–Meier survival curves for IFNG, STAT1 and IRF1 expressing TCGA melanomas56, P values shown from Log-rank tests. Multivariate Pvalues corrected for age: IFNG P=1.79e-05, n=90, 47 events; STAT1 P=3.82e-05, n=90, 33 events; IRF1 P=2.52e-05, n=90, 44 events.

Back to article page